Literature DB >> 32946123

A prospective observational study of the rapid detection of clinically-relevant plasma direct oral anticoagulant levels following acute traumatic injury.

D Oberladstätter1,2, W Voelckel1, C Schlimp1,2, J Zipperle2, B Ziegler3, O Grottke4, H Schöchl1,2.   

Abstract

In urgent clinical situations, such as trauma, urgent surgery or before thrombolysis, rapid quantification of direct oral anticoagulant plasma drug levels is warranted. Using the ClotPro® analyser, we assessed two novel viscoelastic tests for detection of clinically-relevant plasma drug levels in trauma patients. The ecarin clotting time was used to assess the plasma concentration of dabigatran and Russell´s viper venom clotting time to determine the plasma concentration of direct factor Xa inhibitors. In parallel, plasma concentrations were analysed using plasma-based chromogenic assays. A total of 203 simultaneous measurements were performed. Strong to very strong linear correlations were detected between ecarin clotting time and plasma concentration of dabigatran (r = 0.9693), and between Russell´s viper venom clotting time and plasma concentrations of apixaban (r = 0.7391), edoxaban (r = 0.9251) and rivaroxaban (r = 0.8792), all p < 0.001. An ecarin clotting time ≥ 189 seconds provided 100% sensitivity and 90% specificity for detecting plasma dabigatran concentrations ≥ 50 ng.ml-1 . Corresponding Russell´s viper venom clotting time cut-off values were ≥ 136 seconds for apixaban (80% sensitivity, 88% specificity), ≥ 168 seconds for edoxaban (100% sensitivity, 100% specificity) and ≥ 177 seconds for rivaroxaban (90% sensitivity, 100% specificity). Detection of drug levels ≥ 100 ng.ml-1 was also investigated: for dabigatran, an ecarin clotting time ≥ 315 seconds yielded 92% sensitivity and 100% specificity; while Russell´s viper venom clotting time cut-offs of 191, 188 and 196 seconds were calculated for apixaban (67% sensitivity, 88% specificity), edoxaban (100% sensitivity, 75% specificity) and rivaroxaban (100% sensitivity, 91% specificity), respectively. We have demonstrated strong positive correlations between plasma drug levels and clotting time values in the specific ClotPro assays. Cut-off values for detecting clinically-relevant drug levels showed high levels of sensitivity and specificity.
© 2020 Association of Anaesthetists.

Entities:  

Keywords:  ClotPro; ECA-test; RVV-test; direct oral anticoagulant

Year:  2020        PMID: 32946123     DOI: 10.1111/anae.15254

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  10 in total

1.  Delayed Surgery Does Not Reduce Transfusion Rates in Low-Energy Hip Fractures on Direct Oral Anticoagulants.

Authors:  Ashley E Levack; Harold G Moore; Stephen Stephan; Sally Jo; Ian Schroeder; John Garlich; Aidan Hadad; Milton T M Little; Anna N Miller; Stephen Lyman; Joseph Lane
Journal:  J Orthop Trauma       Date:  2022-04-01       Impact factor: 2.512

2.  [Principles of the perioperative management of direct oral anticoagulants].

Authors:  Maik von der Forst; Benedict Morath; Martina Schwald; Markus A Weigand; Felix C F Schmitt
Journal:  Anaesthesiologie       Date:  2022-06-15

Review 3.  Anticoagulation Monitoring for Perioperative Physicians.

Authors:  Cheryl L Maier; Roman M Sniecinski
Journal:  Anesthesiology       Date:  2021-10-01       Impact factor: 8.986

Review 4.  [Anticoagulation in intensive care medicine].

Authors:  Patrick Möhnle; Mathias Bruegel; Michael Spannagl
Journal:  Med Klin Intensivmed Notfmed       Date:  2021-08-25       Impact factor: 1.552

5.  Impaired fibrinolysis in critically ill COVID-19 patients.

Authors:  Mirjam Bachler; Johannes Bösch; Daniel P Stürzel; Tobias Hell; Andreas Giebl; Mathias Ströhle; Sebastian J Klein; Volker Schäfer; Georg F Lehner; Michael Joannidis; Claudius Thomé; Dietmar Fries
Journal:  Br J Anaesth       Date:  2020-12-09       Impact factor: 9.166

6.  Predictive ability of viscoelastic testing using ClotPro® for short-term outcome in patients with severe Covid-19 ARDS with or without ECMO therapy: a retrospective study.

Authors:  Lars Heubner; Marvin Greiner; Oliver Vicent; Jan Beyer-Westendorf; Oliver Tiebel; Ute Scholz; Andreas Güldner; Martin Mirus; Dietmar Fries; Thea Koch; Peter Markus Spieth
Journal:  Thromb J       Date:  2022-08-29

7.  Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop.

Authors:  Viktor Taune; Mika Skeppholm; Anna Ågren; Agneta Wikman; Andreas Hillarp; Håkan Wallén
Journal:  TH Open       Date:  2022-08-29

8.  Modified thromboelastometric tests provide improved sensitivity and specificity to direct oral anticoagulants compared to standard thromboelastometric tests in-vitro.

Authors:  Philipp Groene; Jennifer Butte; Sarah Thaler; Klaus Görlinger; Simon T Schäfer
Journal:  Thromb J       Date:  2022-07-21

9.  A comparison of the ClotPro system with rotational thromboelastometry in cardiac surgery: a prospective observational study.

Authors:  Ryogo Yoshii; Teiji Sawa; Hidetake Kawajiri; Fumimasa Amaya; Kenichi A Tanaka; Satoru Ogawa
Journal:  Sci Rep       Date:  2022-10-14       Impact factor: 4.996

Review 10.  Diagnostic Modalities in Critical Care: Point-of-Care Approach.

Authors:  Sasa Rajsic; Robert Breitkopf; Mirjam Bachler; Benedikt Treml
Journal:  Diagnostics (Basel)       Date:  2021-11-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.